These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19238540)

  • 1. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
    Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
    Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
    Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
    J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
    Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
    Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
    Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
    Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
    Campia U; Nodari S; Gheorghiade M
    Curr Heart Fail Rep; 2010 Sep; 7(3):100-9. PubMed ID: 20625945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Istaroxime: a new luso-inotropic agent for heart failure.
    Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
    Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
    Wehrens XH
    Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
    Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
    Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
    Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
    Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
    Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
    Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
    Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.
    Arici M; Ferrandi M; Barassi P; Hsu SC; Torre E; Luraghi A; Ronchi C; Chang GJ; Peri F; Ferrari P; Bianchi G; Rocchetti M; Zaza A
    J Pharmacol Exp Ther; 2023 Jan; 384(1):231-244. PubMed ID: 36153005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
    Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Istaroxime in heart failure new hope or more hype.
    Dec GW
    J Am Coll Cardiol; 2008 Jun; 51(23):2286-8. PubMed ID: 18534277
    [No Abstract]   [Full Text] [Related]  

  • 17. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
    Torre E; Arici M; Lodrini AM; Ferrandi M; Barassi P; Hsu SC; Chang GJ; Boz E; Sala E; Vagni S; Altomare C; Mostacciuolo G; Bussadori C; Ferrari P; Bianchi G; Rocchetti M
    Cardiovasc Res; 2022 Mar; 118(4):1020-1032. PubMed ID: 33792692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
    Ferrari P; Micheletti R; Valentini G; Bianchi G
    Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
    Rocchetti M; Alemanni M; Mostacciuolo G; Barassi P; Altomare C; Chisci R; Micheletti R; Ferrari P; Zaza A
    J Pharmacol Exp Ther; 2008 Sep; 326(3):957-65. PubMed ID: 18539651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular Mechanisms Underlying the Low Cardiotoxicity of Istaroxime.
    Racioppi MF; Burgos JI; Morell M; Gonano LA; Vila Petroff M
    J Am Heart Assoc; 2021 Jul; 10(14):e018833. PubMed ID: 34219467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.